Patent intelligence · US
US 11992530
Therapeutic uses for sodium thiosulfate and formulations
Therapeutic uses for sodium thiosulfate and formulations
Patent details — US 11992530
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 28, 2024
- Expiration
- May 23, 2044
- Applicant
- Fennec Pharn ceuticals Inc.
- Claims
- 26
- CPC classes
- A61K, A61K33/04, A61K33/243, A61K47/02
Quick answer
US 11992530 (Therapeutic uses for sodium thiosulfate and formulations) is held by Fennec Pharn ceuticals Inc.. Status: granted. Granted May 28, 2024. Expires May 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Fennec Pharn ceuticals Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K33/04, A61K33/243, A61K47/02, A61K47/18, A61K47/183
More from Fennec Pharn ceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12311026
Therapeutic uses for sodium thiosulfate formulations
granted -
US 11998604
Therapeutic uses for sodium thiosulfate formulations
granted -
US 11964018
Therapeutic uses for sodium thiosulfate formulations
granted -
US 11617793
Anhydrous sodium thiosulfate and formulations thereof
granted -
US 11510984
Anhydrous sodium thiosulfate and formulations thereof
granted -
US 11291728
Anhydrous sodium thiosulfate and formulations thereof
granted -
US 10792363
Anhydrous sodium thiosulfate and formulations thereof
granted
Frequently asked questions
What is US patent 11992530?
US 11992530 (Therapeutic uses for sodium thiosulfate and formulations) is held by Fennec Pharn ceuticals Inc.. Status: granted. Granted May 28, 2024. Expires May 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11992530?
Fennec Pharn ceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 11992530 expire?
Our index shows an expiration date of May 23, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.